ClinicalTrials.gg
Active, not recruitingNCT05870488STACIUpdated Aug 6, 2026

iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction

A Phase 4 interventional study of Use of iFuse TORQ in Sacroiliac Joint Dysfunction, Sacroiliac; Fusion and Sacroiliac Disorder, sponsored by SI-BONE, Inc.. Active, not recruiting at 14 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by SI-BONE, Inc. · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.

Planned enrollment
33rd of 88
110 · median 82
Started
2023
with 3 others
Phase 4
6 of 106
1 open now
Primary completion
2025-04
later than 3 of 22 live
Registered
91st of 106
by date
Lead sponsor
3 of 106
SI-BONE, Inc.

Among the 106 studies in Arthralgia with a site in United States, this one is the 33rd largest by planned enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2023, is one of 6 in phase 4, reaches primary completion later than 3 of the 22 other live ones, and was the 91st registered.

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

Browse Arthralgia studies →

Open to participants now

17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Arthralgia with a site in United States, or all of them as a file.
02

Study summary

iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction (STACI) is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system.

Read the detailed description

This trial is a prospective, multicenter, study of SIJ fusion using the iFuse TORQ implant system. The goal of the trial is to demonstrate the effectiveness of the device for its intended use.

03

Conditions studied

  • Sacroiliac Joint Dysfunction
  • Sacroiliac; Fusion
  • Sacroiliac Disorder
  • Sacroiliac Joint Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 21 at time of screening
  2. Patient has lower back / buttock pain for at least 6 months inadequately responsive to non-surgical care
  3. Diagnosis of sacroiliac joint dysfunction (degenerative sacroiliitis or sacroiliac disruption)
  4. Baseline Oswestry Disability Index (ODI) score of at least 30%
  5. Baseline SIJ pain score of at least 5 on 0-10 numerical rating scale
  6. \< 35
  7. Patient has signed study-specific form

Exclusion criteria

Exclusion Criteria:

  1. 4 or 5
  2. Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture
  3. Other known sacroiliac pathology such as: inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy), tumor, infection, acute fracture
  4. Cluneal neuralgia
  5. Previous SIJ implant placement, including allograft
  6. Anatomic anomalies/defects that would preclude safe and/or biomechanically acceptable device placement
  7. History of recent (\<1 year) major trauma to pelvis
  8. Previously diagnosed or suspected severe osteoporosis (defined as prior T-score \< -2.5 or history of osteoporotic fracture).
  9. Chronic rheumatologic condition (e.g., rheumatoid arthritis)
  10. Current diagnosis of fibromyalgia
  11. Known allergy to titanium or titanium alloys
  12. Current local or systemic infection that raises the risk of surgery
  13. Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation
  14. Currently pregnant or planning pregnancy in the next 2 years (self-reported)
  15. Patient is a prisoner or a ward of the state.
  16. Known or suspected active drug or alcohol abuse, including opioids
  17. Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
  18. Currently participating in another interventional clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Other
    Use of iFuse TORQ for SI Joint Fusion

    Participants with SI joint dysfunction are treated with iFuse TORQ.

    Device: Use of iFuse TORQ

Interventions

  • DeviceUse of iFuse TORQ

    Use of iFuse TORQ for the treatment of SI Joint dysfunction

06

What researchers measure

Primary outcomes

  1. Change in SI joint pain measured by numerical rating scale (NRS)

    Change in SI joint pain measured by NRS (0- no pain to 10- worst pain imaginable)

    Time frame: At baseline and 6 months

Secondary outcomes

  1. Improvement from baseline in SI joint (SIJ) pain

    Improvement from baseline in SIJ pain as measured by numeric rating scale (0- no pain to 10- worst pain imaginable).

    Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months

  2. Improvement from baseline in disability

    Improvement from baseline in disability as measured by Oswestry Disability Index

    Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months

  3. Improvement from baseline in quality of life

    Improvement from baseline in aggregate quality of life and individual domains as measured by PROMIS-29.

    Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months

  4. Proportion of subjects with a complication rated as probably or definitely related to the procedure or device.

    Time frame: At baseline, 1-, 3-, 6-, 12-, and 24-months

  5. Evidence of bone binding

    Evidence of bone binding to at least 50% of the porous surface area of each implanted device

    Time frame: At baseline and 24 months

  6. Proportion of treated sides showing signs of loosening of iFuse TORQ or other instrumentation

    Proportion of treated sides showing signs of loosening of iFuse TORQ or other instrumentation, as evidenced by both radiopaque areas around implant plus bony reaction ("rind") near implant

    Time frame: At baseline and 24 months

  7. Proportion of iFuse TORQ implants that show evidence of device migration

    Time frame: At baseline and 24 months

  8. Proportion of iFuse TORQ implants that show breakage

    Time frame: At baseline and 24 months

07

Study locations

14 sites
  • Napa Valley Orthopaedics
    Napa, California 94558, United States
  • Source Healthcare
    Santa Monica, California 90403, United States
  • Comprehensive Pain and Spine Specialists
    Shelbyville, Indiana 46176, United States
  • Ascentist Healthcare
    Leawood, Kansas 66211, United States
  • Crimson Pain Management
    Overland Park, Kansas 66209, United States
  • University of Kentucky
    Lexington, Kentucky 40504, United States
  • Clearway Pain
    Annapolis, Maryland 21401, United States
  • St Louis Pain Consultants
    Chesterfield, Missouri 63017, United States
  • Nevada Advanced Pain
    Reno, Nevada 89511, United States
  • Clinical Investigations
    Edmond, Oklahoma 73034, United States
  • Neurological Associates of Lancaster
    Lancaster, Pennsylvania 17601, United States
  • Advanced Pain Institute of Texas
    Lewisville, Texas 75057, United States
  • Anesis Spine & Pain Care
    Renton, Washington 98057, United States
  • Pro Spine and Pain
    Milwaukee, Wisconsin 53221, United States
08

References and documents

Publications

  • Weisbein J, Patterson D, Beall D, Nguyen D, Smith J, Harstroem C, Davis T, Foster J, Christopher A, Kloster D, Broadnax J, Anderson E, Hatheway J, Trobridge A, Simmons C, Stauss T, Harned M, Mallard C. Safety and initial effectiveness of minimally invasive sacroiliac joint fusion with metal implants using a lateral transiliac approach: a prospective trial. Pain Med. 2025 Dec 1;26(12):918-923. doi: 10.1093/pm/pnaf082. PubMed 40574607 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Apr 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
May 23, 2023
StartActual
May 23, 2023
Primary completionActual
Apr 23, 2025
CompletionEst.
Nov 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05870488
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
May 23, 2023
Start date
May 23, 2023
Primary completion
Apr 23, 2025
Completion
Nov 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Stacie Tran, MPH
study director · SI-BONE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion